Rare-Disease Genomics PhD: How Rare Variants Affect Musculoskeletal Disorders

Rare-Disease Genomics PhD: How Rare Variants Affect Musculoskeletal Disorders

Quick Decision

This four-year MRC FGx-DLA project links Exeter population genetics with an Oxford laboratory-validation stage for musculoskeletal-disease variants. The advertised chain runs from phenotype construction and rare/structural-variant analysis through eQTL/pQTL evidence to CRISPR-Cas9, transcriptomics and cellular phenotyping. It suits applicants seeking both computational and experimental functional-genomics experience. The named resources’ sequencing content and access, as well as the division of work across sites, need confirmation.

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

Genome-wide association studies have identified many common variants associated with musculoskeletal disease, but association alone often does not reveal which variant is causal or how it changes tissue biology. The project proposes rare variants as one route to more interpretable signals because their effects can be larger and their correlation with neighbouring variants lower. Its goal is to connect genotype to disease mechanisms and then test selected candidates in relevant human models.

The scientific case is credible, but rare does not automatically mean easy to interpret. Reliable rare-variant work depends on well-defined phenotypes, adequate carrier counts, ancestry-aware quality control and a suitable gene- or region-level test. The student's proposed phenotype work—combining electronic health records with assessment data—is therefore substantive research, not a preliminary data-cleaning task. Diagnostic codes, self-report, surgery and clinical measures may capture different disease severities or subtypes; the project description does not say how those definitions will be compared or validated.

Advertised Work, Methods and Scope

The project PDF sets out three linked objectives: identify rare variants associated with musculoskeletal disorders in WGS resources; establish the functional consequences of prioritised variants in disease-relevant primary human cell and tissue models; and trace pathways from genotype to disease to identify possible therapeutic targets. Its two phases are:

1. Exeter computational phase. Define musculoskeletal phenotypes by combining health records and assessment data; test rare and structural variants; integrate multi-omic evidence such as eQTLs and pQTLs; and use bioinformatics pipelines and statistical modelling to prioritise candidate genes and regulatory regions.
2. Oxford experimental phase. Test top-prioritised candidates using primary human cells, ex-vivo tissue and the project-described “humanoid robotic bioreactors”. Listed methods include CRISPR-Cas9 editing, transcriptomics and cellular phenotyping to assess effects on cell function.

The intended output is validated causal genes and clearer disease pathways, with possible drug-repurposing targets. These are project aims, not guaranteed results. The public description does not identify the lead disease for the student, the expected number of variants, how candidates will pass from computational to experimental work, or the duration of each phase. The Oxford cluster's own description includes osteoarthritis, Dupuytren's disease, frozen shoulder and carpal tunnel; the student's exact disease scope is still open. The official Oxford MSK cluster page describes the broader cluster, but does not establish that every disease or named cluster investigator will be part of this student's work.

The biobank language also needs a data-by-data interpretation. A 2025 Nature paper reports WGS for 490,640 UK Biobank participants and cross-ancestry analyses, while noting that most disease-trait associations were primarily observed in participants of European ancestry. An All of Us programme paper reported 245,388 WGS sequences in its 2024 release; its 2025 v8 release summary reports 414,830 short-read WGS participants and 97,061 structural-variant calls. By contrast, Our Future Health's May/June 2026 release describes 755,000 participants with genotype-array and imputed-genotype data, and more than two million questionnaire records; WGS is not listed in its current data catalogue. The project may be describing future sequencing, an approved external analysis, or a planned imputation/WGS mix, but it has not said which. The wording “millions” should not be read as millions of WGS genomes already available in each named cohort. UK Biobank WGS study · All of Us WGS release paper · All of Us 2024 programme data review · Our Future Health current data catalogue · Our Future Health June 2026 release

The named cohorts are not immediately interchangeable. UK Biobank access is application-based and its current page says new applications are paused during Research Analysis Platform changes, with new applications intended to resume in late 2026. All of Us genomic data sit in the Controlled Tier, requiring institutional agreement and researcher credentials/training. Our Future Health requires researcher registration, study-specific Access Board approval, paid access and analysis in its Trusted Research Environment. Data access and transfer costs, harmonisation, phenotype definitions and approval timing could shape the thesis more than the headline sample size suggests. UK Biobank access status · NIH All of Us researcher access · Our Future Health access process

Recent Research That Helps Frame the Project

• Hawkes et al. (2026), rare and common WGS associations across 672,976 people. This paper uses aggregate rare-variant tests to identify coding and non-coding associations and shows how rare-variant signals can converge with common-variant findings. It is the closest methods example listed in the project PDF, but its outcomes are height, BMI and waist-to-hip ratio—not musculoskeletal disease. It supports asking which test and variant-to-gene prioritisation strategy the studentship will use, not assuming a particular result. Nature Communications paper
• Hatzikotoulas et al. (2025), osteoarthritis in 1,962,069 individuals. The study reports 962 independent associations, including 513 not previously reported, and integrates single-cell and other molecular data to prioritise effector genes. Its ancestry mix is still 87.31% European, despite being a multi-ancestry analysis. It shows the scale of existing common-variant and multi-omic OA research, and why the proposed rare-variant and tissue-validation angle should add mechanistic evidence rather than repeat locus discovery. Nature paper
• Riesmeijer et al. (2024), Dupuytren's disease. Across 11,320 cases and 47,023 controls, the meta-analysis identified 85 significant SNPs at 56 loci, 11 of them novel, and implicated Hedgehog and Notch signalling. This gives a substantial common-variant map for one disease named in the project, but it does not substitute for rare-variant tests or functional validation. Nature Communications paper
• Green et al. (2021), frozen shoulder. The study identified five associated loci and reported Mendelian-randomisation evidence linking type 1 diabetes to frozen-shoulder risk. It is a disease-relevant prior study associated with the named lead supervisor, though it focuses on common-variant associations and does not by itself establish the methods or day-to-day supervision for this studentship. PLOS Genetics paper

Together, these papers make the project scientifically timely: common-variant maps and large cohorts provide candidate signals, while rare-variant analysis and tissue models may help move toward mechanisms. A useful question is how the team will manage the gap between association evidence, candidate prioritisation and disease-relevant experimental models, especially if phenotype or WGS availability differs by cohort.

School, Programme and Field Context

The official project PDF names the University of Exeter as the primary institution, locates the department in Clinical and Biomedical Sciences and describes Oxford as the laboratory phase. Exeter has a relevant MPhil/PhD Clinical and Biomedical Sciences route and a Genetics, Genomics and Epigenetics theme spanning genome sequencing, common and rare disease, functional genomics and clinical genetics. The national FGx-DLA adds shared scientific meetings, cohort training and collaboration across six partner universities. The DLA webpage describes cross-institutional supervisory teams, but the project PDF names only Harry Green as lead supervisor. It does not explicitly state the student's formal registration, exact degree title, degree-awarding authority, campus arrangement or Oxford co-supervisors. No joint or dual degree should be inferred from the two-site design. Exeter programme page · Exeter genomics theme · FGx-DLA structure

Exeter's REF 2021 profile reports that 45% of its Clinical Medicine research activity was rated 4-star and 48% 3-star; its Biological Sciences profile was 41% 4-star and 49% 3-star. These are subject-unit quality profiles, not evaluations of this one project or a prediction of doctoral experience. Exeter's programme page also describes the department's research facilities and its NIHR Biomedical Research Centre connections; access to any particular platform or patient tissue for this project should be confirmed separately. REF 2021 results

Dr Harry Green is a lecturer in health data science whose official profile describes a background in pure mathematics and cardiac biophysics, research in predictive modelling and causal inference using genetics, and work combining clinical records with genetic risk information. This is a relevant profile for the Exeter analysis phase. The Oxford MSK cluster supplies a distinct translational environment focused on disease genetics, surgery-derived tissue and functional biology. A separate Oxford humanoid bioreactor project describes robotic loading of tissue-engineering constructs and biomaterial testing. That platform is an interesting feature, but its public description frames it as an experimental tissue-engineering platform; it does not establish that it is validated or scheduled for this project's specific variant assays. Harry Green profile

Field and Career Context

The research direction combines statistical genetics, bioinformatics, functional genomics, cell biology and translational musculoskeletal research. Recent work points to continued value in rare variant association and gene-level testing, but high sample size alone does not resolve unequal ancestry representation, phenotype misclassification or how to select a tractable variant for experimental study. A defensible thesis could focus on a specified disease phenotype, compare results across data types or ancestry groups, and test a manageable set of candidates; these are possible designs to discuss, not promised work packages.

Skills England's 2026 Life Sciences assessment projects 66,000 additional priority-occupation jobs (44%) and 52,000 replacement needs during 2025–2035. It highlights data, digital and scientific skills, but its occupation categories are broad, projections are explicitly uncertain and the figures are not a count of genomics PhD jobs. Likely pathways include statistical genetics and bioinformatics in universities, health research, biotech or pharmaceutical discovery, and functional genomics or assay development. Some clinical-genomics and regulated roles have separate professional or clinical requirements. Career direction will depend on building a strong, reproducible analysis portfolio as well as practical understanding of functional assays. Skills England Life Sciences assessment · Exeter graduate career context

Supervisor and Lab Assessment

The lead supervisor's profile fits the statistical-genomics and health-data aspects, while the official PDF says the Oxford phase will draw on molecular genetics and cellular models in the HFGI Musculoskeletal Cluster. The two-site structure could provide both analytical and experimental training, an uncommon combination for a single studentship. However, public materials do not state who will co-supervise the Oxford work, how frequently the team will meet across sites, who decides which candidates reach the lab phase, or whether tissue, experimental staff and sequencing/data-compute budgets are already secured.

Exeter's genomics theme confirms broad institutional activity in rare-disease sequencing, genomic variation and functional genomics. Oxford's cluster lists relevant expertise in bioinformatics, cell assays, tissue and bioreactors. These signals support the plausibility of the planned work but do not prove student-specific instrument access, sample availability or guaranteed data permissions. The project PDF mentions HPC and patient-tissue resources; ask which resources are already approved for the studentship and what training is planned in statistical genetics, secure-cloud analysis, CRISPR, tissue culture and reproducible computing.

Funding, Application and Living Costs

The Exeter FGx-DLA page states that these are four-year full-time studentships, with UK tuition fees, a stipend matching the UK Research Council minimum (£21,805 per year for 2026/27, updated annually), and up to £5,000 per year in additional research training and support funding. It says the awards are open to UK and international students. The project PDF is consistent with the four-year DLA structure and application timetable; the collected listing states that fees and a stipend are funded for up to four years.

The international fee rule is clarified by the national programme page. The Exeter DLA page specifies UK tuition fees, and UKRI general guidance says its tuition contribution is capped at the Home rate; international students may therefore need to contribute more under some awards. The national FGx-DLA page explicitly states that international students at Exeter do not need to supplement UKRI funding. For this Exeter project, the published programme rule therefore resolves the apparent fee gap. Confirm that the written award offer and annual fee statements reflect it. The up-to-£5,000 annual training/support fund is project support, not additional personal living income. Exeter DLA funding rules · National FGx-DLA international-fee guidance · UKRI student fee and stipend guidance

The £21,805 2026/27 stipend is about £1,817 per month before considering any future uplift. Exeter estimates £1,300–£2,000 per month for a single student in Exeter/Cornwall, based on April 2026 local spending. Oxford estimates £1,405–£2,105 per month for 2026/27. At the top of those ranges, the current monthly stipend would fall short by about £183 in Exeter and £288 in Oxford; these are comparisons of published guides, not a personal budget. Visa and immigration-health costs, travel between sites, relocation, dependants and rent choices can add pressure. Clarify the Oxford residence schedule and whether travel/temporary accommodation is funded from the separate research-support allocation. Exeter living-cost estimate · Oxford living-cost estimate

The award page lists a deadline of 5 January 2027 for September 2027 entry. Applicants use the University of Exeter portal for an online application and a separate FGx-DLA Applicant Questionnaire. The questionnaire allows up to three project preferences, but only one application per person is accepted. Missing documents prevent shortlisting. Two references are required; referees must not be members of the prospective supervisory team. If shortlisted, applicants must arrange for academic references to reach Admissions seven days before interviews. Documents must be in English; certified translations of qualifications are required. Questionnaire prompts include motivation and aspirations, an achievement and what was learned, research experience/process, and disclosure of any generative-AI use in preparing the application. Confirm the exact required document list and portal deadline time in the live application system. Official DLA application criteria · Project-specific application instructions

Applicant Fit and Preparation

Required Background and Skills

The DLA requires at least a relevant 2:1 Honours undergraduate degree or international equivalent. Listed subject areas include genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions, bioinformatics, computer science and statistics. The usual English-language benchmark is IELTS 7.0 overall with no component below 6.5, or an accepted equivalent; evidence must reach the University by the deadline. Two references and complete English-language application documents are required. These are the published DLA conditions; the project description does not add a separate programming, CRISPR or prior laboratory-experience requirement.

Preferred Experience and Suggested Preparation

No preferred experience is formally identified in the project PDF. Applicants may strengthen their case by showing experience in one or more relevant areas: statistical genetics, GWAS or rare-variant methods, phenotype construction from health records, R/Python and reproducible workflows, multi-omics, molecular genetics, CRISPR or primary-cell/tissue work. The two-phase design does not imply that one candidate must already be expert in every method. In the application questionnaire, a concrete example of learning a new research method, handling messy data, evaluating uncertainty or connecting an analysis to biological interpretation would be more persuasive than a generic claim of interdisciplinary interest.

Next Actions and Questions to Verify

Before Applying

1. Which cohort currently supplies WGS, genotype arrays or imputed data for each disease, and how does the plan account for Our Future Health's current lack of a listed WGS release?
2. Has the team obtained or applied for UK Biobank access, and what is the contingency if the current pause or approval timing affects project start?
3. Which disease or diseases are in scope, and what does “millions of individuals” refer to by cohort, data type and expected analysis sample size?
4. Does the written offer confirm that Exeter international students do not supplement UKRI funding, and does the award cover tuition and stipend for all four years with annual updates?
5. Is the deadline 5 January 2027 for both stages, and which test/qualification documents and references must be in place at that point?

At Interview

1. Who will supervise the Oxford experimental phase, how will supervision work across Exeter and Oxford, and how much time is expected at each site?
2. How will phenotype definitions, ancestry-aware QC and rare-variant burden tests be selected and validated?
3. What is the decision gate from computational candidate to experiment, and what are the expected numbers of variants, genes and assays?
4. Are disease-relevant primary cells, ex-vivo tissues and patient biobanks already available under approvals? Which CRISPR and transcriptomic methods are planned?
5. Is the humanoid bioreactor a committed component of this student's experimental plan, an optional model, or a capability in the wider cluster?
6. Which shared training, cohort activities and up-to-£5,000 annual research-support costs are available to this project, and what travel between sites is budgeted?

Before Accepting an Offer

1. Obtain the final written fee-status breakdown, award duration, stipend schedule, registration/degree details and any required Oxford residency or travel costs.
2. Confirm the approved dataset plan, what data are available at project start, access fees and compute costs, and how the thesis will proceed if a named resource or phenotype is delayed.

Evidence and Sources

Project, Programme and Institution

• Official project description and application steps
• MRC Functional Genomics Doctoral Landscape Award
• Clinical and Biomedical Sciences PhD route
• Genetics, Genomics and Epigenetics theme
• Exeter REF 2021 subject results
• FGx-DLA recruitment and partner network

Supervisor, Research Cluster and Papers

• Harry Green — NIHR Exeter Biomedical Research Centre
• Oxford UK Human Functional Genomics Initiative Musculoskeletal Cluster
• Oxford Humanoid Bioreactor Project
• Rare and common WGS associations across 672,976 people (2026)
• Translational genomics of osteoarthritis in 1,962,069 individuals (2025)
• Dupuytren's disease GWAS meta-analysis (2024)
• Frozen shoulder GWAS and diabetes analysis (2021)

Biobanks, Funding and Cost

• UK Biobank WGS paper
• UK Biobank application status and access route
• All of Us genomic data-release paper
• All of Us 2024 release review
• NIH All of Us access criteria
• Our Future Health data catalogue
• Our Future Health data access process
• Our Future Health May/June 2026 data release
• UKRI support for funded students
• FGx-DLA international-fee guidance for Exeter students
• Exeter living-cost estimate
• Oxford living-cost estimate
• Skills England Life Sciences assessment (2026)